Extract
No longer recognised as a single disease entity with a “one size fits all” approach to treatment, asthma is an umbrella diagnosis spanning different endotypes and clinical phenotypes. The discovery of T2 inflammation as a driver in many asthma patients transformed our understanding of this disease and inspired the discovery of targeted biological therapies [1]. T2 inflammation is mediated by cytokines including interleukin (IL)-4, IL-5 and IL-13, which then regulate the production of measurable biomarkers including IgE, blood and sputum eosinophils, and fractional exhaled nitric oxide (FeNO) [2].
Abstract
There is a need for stable biomarkers of endotype for asthma across the lifecourse to provide earlier precision medicine approaches https://bit.ly/3PAS19i
Footnotes
Conflict of interest: L. Perrem reports advisory board honoraria from Sanofi. P. Subbarao reports grants from CIHR, Canada Research Chairs, Tier 1, Genome Ontario, Don and Debbie Morrison; participation on advisory board for OSMB NIH, outside of the submitted work.
- Received May 19, 2022.
- Accepted August 15, 2022.
- Copyright ©The authors 2022. For reproduction rights and permissions contact permissions{at}ersnet.org
LIBRARY USERS
Log in through your institution
Purchase access
